Nelivaptan

Nelivaptan
Clinical data
Routes of; administration	Oral
ATC code	none;
Identifiers
	IUPAC name (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide;
CAS Number	439687-69-1 ;
PubChem CID	9895468;
IUPHAR/BPS	2202;
ChemSpider	8071134 ;
UNII	3TY57MQ4OA;
ChEMBL	ChEMBL582857 ;
CompTox Dashboard (EPA)	DTXSID7047358 ;
ECHA InfoCard	100.210.987
Chemical and physical data
Formula	C30H32ClN3O8S
Molar mass	630.11 g·mol−1
	InChI InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1 ; Key:NJXZWIIMWNEOGJ-WEWKHQNJSA-N ;
	(what is this?) (verify)

Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V_1B subtype.[2] The drug had entered clinical trials for treatment of anxiety and depression.[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.[4]

References

World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4): 341.
Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews. 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMC 6741711. PMID 15867952.
"Second-quarter 2008 results" (PDF). Press Release. Sanofi-Aventis. 2008-07-31. Archived from the original (PDF) on 2008-12-06. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).

SSR149415 at the US National Library of Medicine Medical Subject Headings (MeSH)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.